Hikma reiterates guidance for 2015
Jordanian drugmaker Hikma Pharmaceuticals (LSE: HIK) says it has made a good start to the year and reiterates its guidance for 2015 for the group overall and for each of its business segments. The company’s share price gained 2.1% to £20.72 in morning trading on the London Stock Exchange.
The company continues to expect full year group revenue growth of around 6% in constant currency, following an extremely strong year in 2014, in which profit attributable to shareholders increased by 30%. On a reported basis, it expects full year group revenue growth of around 2%, reflecting foreign exchange rate movements in the year to date. For the first half, it expects group revenue in constant currency to be broadly in line with the same period last year. For 2014, the company posted group revenue of $1.49 billion, a rise of 9% on 2013 (The Pharma Letter March 11).
Injectables
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze